Pulse Biosciences (NASDAQ:PLSE) Raised to “Sell” at StockNews.com

StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE) to a sell rating in a research report sent to investors on Thursday.

Pulse Biosciences Stock Performance

Shares of PLSE stock opened at $17.65 on Thursday. Pulse Biosciences has a 52 week low of $6.59 and a 52 week high of $22.69. The stock’s fifty day moving average is $17.68 and its 200-day moving average is $16.42.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same quarter in the previous year, the company posted ($0.19) earnings per share.

Insider Activity at Pulse Biosciences

In other news, Director Robert W. Duggan acquired 56,054 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The stock was purchased at an average price of $17.35 per share, for a total transaction of $972,536.90. Following the completion of the acquisition, the director now owns 42,228,057 shares in the company, valued at $732,656,788.95. This trade represents a 0.13 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 71.50% of the stock is currently owned by company insiders.

Institutional Trading of Pulse Biosciences

Several hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD bought a new position in shares of Pulse Biosciences during the 1st quarter valued at about $88,000. Quest Partners LLC bought a new position in Pulse Biosciences in the second quarter valued at approximately $91,000. Cetera Advisors LLC acquired a new position in shares of Pulse Biosciences in the first quarter valued at approximately $109,000. Rhumbline Advisers increased its position in shares of Pulse Biosciences by 6.7% during the second quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock worth $288,000 after acquiring an additional 1,608 shares in the last quarter. Finally, Franklin Resources Inc. bought a new stake in Pulse Biosciences in the 3rd quarter valued at $378,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.